$132.26
-3.08-2.28%
Last update: Nov 10, 2:03 PM
Twist Bioscience Corp
TWSTNASDAQ
Twist Bioscience rose 337.1% from $30.96 to $135.34, ahead of the S&P 500's +10.5%. Its worst day was Oct 6 (−18.6%), and its low came Nov 19 at $25.45.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.45 beat the $-0.46 estimate on $99.0M revenue (est. $97.4M); Q1 revenue guidance of $100.0M–$101.0M against the $99.4M consensus.
−10.1% · S&P 500 0.0%
Story events cover the past 12 months · Times ET
EPS of $-0.50 beat the $-0.50 estimate on $103.7M revenue (est. $102.7M); Q2 revenue guidance of $107.0M–$108.0M against the $104.5M consensus.
+14.0% · S&P 500 +0.5%
Twist Bioscience shares rose 14.0%, while the S&P 500 rose 1.2%.
+14.0% · S&P 500 +1.2%
EPS of $-0.59 missed the $-0.53 estimate on $110.7M revenue (est. $107.7M); FY revenue guidance of $442.0M–$447.0M against the $438.8M consensus.
−7.0% · S&P 500 −0.4%
EPS of $-0.56 missed the $-0.24 estimate on $118.4M revenue (est. $114.5M); FY revenue guidance of $456.0M–$457.0M against the $446.5M consensus.
+10.4% · S&P 500 +1.4%
Twist Bioscience (TWST) stock jumped 17% after Anthropic chose the firm to test AI-designed proteins.
+22.6%, the year's best day · S&P 500 +0.2%
Twist Bioscience shares rose 16.1%, while the S&P 500 fell 0.1%.
+16.1% · S&P 500 −0.1%
Twist Bioscience closed at its highest level of the year, 562.1% above where the year started.
+8.7% · S&P 500 +0.7%
Twist Bioscience shares fell 15.5%, while the S&P 500 fell 0.5%.
−15.5% · S&P 500 −0.5%
Where it ended: a close of $135.34 on Nov 9, 2026. Up next: Q4 2026 earnings on Nov 12, 2026 (EPS est. $-0.25, revenue est. $123.5M).
Nothing in the past 12 months.
All TWST dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TWST and SPY from Benzinga historical bars. Not investment advice.
